Thirdly, [11C]-MET PET was not examined for all patients due to start of therapy or rapid progression of the disease, which significantly restricts the estimation of [11C]-MET PET as a prognostic marker in the gliomas and limits the comparability between [11C]-MET PET and [123I]-VEGF. This evidence concerns the gene VEGFA and central nervous system cancer.